Logos Global Management
Latest statistics and disclosures from Logos Global Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ERAS, ABVX, RVMD, IDYA, BNTX, and represent 29.98% of Logos Global Management's stock portfolio.
- Added to shares of these 10 stocks: BNTX (+$94M), VERA (+$94M), CLDX (+$61M), ABVX (+$47M), DNTH (+$39M), BLTE (+$39M), ACHV (+$35M), COGT (+$35M), CMPS (+$32M), CGON (+$30M).
- Started 25 new stock positions in COGT, Jatt Ii Acquisition Corp, QURE, DBVT, Parabilis Medicines, CMPS, QTTB, BLTE, REPL, ACHV.
- Reduced shares in these 10 stocks: RVMD (-$244M), TERN (-$105M), Centessa Pharmaceuticals (-$84M), CYTK (-$58M), , MDGL (-$45M), , RYTM (-$36M), TYRA (-$33M), ELVN (-$29M).
- Sold out of its positions in BIIB, Centessa Pharmaceuticals, CMPX, CRVS, CYTK, IBIO, JANX, MDGL, MIRM, ORIC. Soleno Therapeutics, TERN, TYRA, UTHR, PCVX, VSTM, ALKS, MGTX, NAMS, PHVS.
- Logos Global Management was a net seller of stock by $-76M.
- Logos Global Management has $2.3B in assets under management (AUM), dropping by 15.98%.
- Central Index Key (CIK): 0001792126
Tip: Access up to 7 years of quarterly data
Positions held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Logos Global Management
Logos Global Management holds 68 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Erasca (ERAS) | 9.6 | $223M | +8% | 12M | 18.32 |
|
| Abivax Sa Sponsored Ads (ABVX) | 5.9 | $137M | +51% | 1.0M | 133.26 |
|
| Revolution Medicines (RVMD) | 5.6 | $131M | -65% | 700k | 187.28 |
|
| Ideaya Biosciences (IDYA) | 4.8 | $112M | -13% | 3.0M | 37.27 |
|
| Biontech Se Sponsored Ads (BNTX) | 4.1 | $94M | NEW | 1.0M | 93.05 |
|
| Vera Therapeutics Cl A (VERA) | 4.1 | $94M | NEW | 2.2M | 42.91 |
|
| Tango Therapeutics (TNGX) | 3.8 | $89M | -5% | 2.9M | 31.26 |
|
| Praxis Precision Medicines I Com New (PRAX) | 3.7 | $87M | -8% | 260k | 334.79 |
|
| Celldex Therapeutics Com New (CLDX) | 3.4 | $78M | +366% | 2.1M | 37.21 |
|
| Dianthus Therapeutics (DNTH) | 3.4 | $78M | +100% | 800k | 97.48 |
|
| Cg Oncology (CGON) | 3.1 | $71M | +73% | 1.0M | 71.05 |
|
| Disc Medicine (IRON) | 2.8 | $64M | +56% | 875k | 73.14 |
|
| Maze Therapeatics (MAZE) | 2.5 | $58M | +56% | 1.9M | 29.84 |
|
| Dyne Therapeutics (DYN) | 2.4 | $57M | +82% | 2.6M | 22.21 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.2 | $52M | +78% | 2.7M | 19.47 |
|
| Ocular Therapeutix (OCUL) | 2.2 | $52M | +37% | 5.3M | 9.82 |
|
| Design Therapeutics (DSGN) | 1.9 | $43M | +53% | 3.0M | 14.47 |
|
| Olema Pharmaceuticals (OLMA) | 1.7 | $40M | 3.2M | 12.51 |
|
|
| Belite Bio Sponsored Ads (BLTE) | 1.7 | $39M | NEW | 250k | 153.99 |
|
| Achieve Life Sciences (ACHV) | 1.5 | $35M | NEW | 5.4M | 6.53 |
|
| Trevi Therapeutics (TRVI) | 1.5 | $35M | -21% | 1.9M | 18.65 |
|
| Cogent Biosciences (COGT) | 1.5 | $35M | NEW | 900k | 38.70 |
|
| Arrivent Biopharma (AVBP) | 1.5 | $35M | +185% | 1.0M | 34.74 |
|
| Crescent Biopharma (CBIO) | 1.5 | $34M | +293% | 1.9M | 18.00 |
|
| Compass Pathways Sponsored Ads (CMPS) | 1.4 | $32M | NEW | 2.3M | 14.15 |
|
| Mineralys Therapeutics (MLYS) | 1.2 | $28M | NEW | 1.1M | 26.98 |
|
| Replimune Group (REPL) | 1.2 | $28M | NEW | 2.5M | 11.07 |
|
| Xenon Pharmaceuticals (XENE) | 1.2 | $27M | 450k | 60.36 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.2 | $27M | 500k | 53.67 |
|
|
| Immunovant (IMVT) | 1.1 | $26M | -38% | 665k | 38.53 |
|
| Jade Biosciences Com New (JBIO) | 1.1 | $25M | +181% | 1.1M | 22.22 |
|
| Enliven Therapeutics (ELVN) | 1.0 | $24M | -55% | 465k | 50.75 |
|
| Veradermics Common Stock (MANE) | 1.0 | $22M | +620% | 180k | 122.94 |
|
| Avalo Therapeutics Com New (AVTX) | 0.9 | $21M | -11% | 1.2M | 18.48 |
|
| Arcus Biosciences Incorporated (RCUS) | 0.9 | $20M | -45% | 650k | 30.83 |
|
| Summit Therapeutics (SMMT) | 0.8 | $20M | NEW | 1.4M | 14.57 |
|
| Immunocore Hldgs Ads (IMCR) | 0.8 | $19M | -60% | 600k | 31.75 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.8 | $19M | -36% | 585k | 32.45 |
|
| Minerva Neurosciences Com New (NERV) | 0.8 | $18M | +2% | 3.3M | 5.55 |
|
| Faeth Therapeutics Com New (FTH) | 0.8 | $18M | +2306% | 722k | 25.00 |
|
| Crispr Therapeutics Namen Akt (CRSP) | 0.7 | $16M | NEW | 300k | 54.54 |
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 0.6 | $15M | NEW | 915k | 16.40 |
|
| Parabilis Medicines | 0.6 | $14M | NEW | 525k | 27.37 |
|
| Rhythm Pharmaceuticals (RYTM) | 0.6 | $14M | -72% | 125k | 111.03 |
|
| Vor Biopharma Com New (VOR) | 0.5 | $12M | -13% | 650k | 18.41 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.5 | $11M | NEW | 200k | 55.00 |
|
| Immix Biopharma (IMMX) | 0.4 | $10M | -18% | 1.0M | 10.31 |
|
| Q32 Bio (QTTB) | 0.4 | $10M | NEW | 800k | 12.74 |
|
| Odyssey Therapeutics Common Stock | 0.4 | $9.8M | NEW | 522k | 18.71 |
|
| Annexon (ANNX) | 0.4 | $8.6M | NEW | 1.5M | 5.71 |
|
| Editas Medicine (EDIT) | 0.3 | $7.2M | NEW | 2.2M | 3.24 |
|
| Relay Therapeutics (RLAY) | 0.3 | $6.5M | -53% | 350k | 18.71 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.3 | $6.3M | -66% | 250k | 25.30 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.3 | $6.3M | -50% | 350k | 17.96 |
|
| Cybin Com New (HELP) | 0.2 | $5.0M | NEW | 750k | 6.61 |
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.2 | $4.4M | NEW | 964k | 4.56 |
|
| Tenax Therapeutics Com New (TENX) | 0.2 | $4.4M | -52% | 300k | 14.55 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.2 | $3.8M | NEW | 80k | 47.04 |
|
| Unicycive Therapeutics Com New (UNCY) | 0.1 | $2.2M | 474k | 4.69 |
|
|
| Palatin Technologies Com New (PTN) | 0.1 | $1.4M | -7% | 130k | 10.79 |
|
| Uniqure Nv SHS (QURE) | 0.1 | $1.4M | NEW | 30k | 46.06 |
|
| Jatt Ii Acquisition Corp Ord Shs | 0.0 | $1.1M | NEW | 100k | 11.36 |
|
| Research Alliance Corp Iii Ord Shs Cl A | 0.0 | $1.1M | NEW | 100k | 10.70 |
|
| Aclaris Therapeutics (ACRS) | 0.0 | $1.1M | -60% | 200k | 5.29 |
|
| Longeveron Cl A New (LGVN) | 0.0 | $905k | NEW | 1.3M | 0.70 |
|
| Fractyl Health (GUTS) | 0.0 | $794k | 1.0M | 0.79 |
|
|
| Septerna (SEPN) | 0.0 | $789k | 24k | 33.49 |
|
|
| Amanat Acquisition Corp Cl A Ord | 0.0 | $508k | NEW | 50k | 10.16 |
|
Past Filings by Logos Global Management
SEC 13F filings are viewable for Logos Global Management going back to 2019
- Logos Global Management 2026 Q2 filed Aug. 14, 2026
- Logos Global Management 2026 Q1 filed May 15, 2026
- Logos Global Management 2025 Q4 filed Feb. 17, 2026
- Logos Global Management 2025 Q3 filed Nov. 14, 2025
- Logos Global Management 2025 Q2 filed Aug. 14, 2025
- Logos Global Management 2025 Q1 filed May 15, 2025
- Logos Global Management 2024 Q4 filed Feb. 14, 2025
- Logos Global Management 2024 Q3 filed Nov. 14, 2024
- Logos Global Management 2024 Q2 amended filed Aug. 27, 2024
- Logos Global Management 2024 Q2 filed Aug. 14, 2024
- Logos Global Management 2024 Q1 filed May 15, 2024
- Logos Global Management 2023 Q4 filed Feb. 14, 2024
- Logos Global Management 2023 Q3 filed Nov. 14, 2023
- Logos Global Management 2023 Q2 filed Aug. 14, 2023
- Logos Global Management 2023 Q1 filed May 15, 2023
- Logos Global Management 2022 Q4 filed Feb. 14, 2023